Orphan Drug Spending: Could Sequence Of Indications Offer Pricing Policy Solution?

 
• By Sarah Karlin-Smith

Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.

mostly wooden stick figures with one blue stick figure
Partial-orphan drug spending and policy solutions are outlined in new Health Affairs study • Source: Shutterstock

More from Rare Diseases

More from Pink Sheet